BELLUS Health Total Assets 2011-2025 | BLU

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.

Main categories of assets
Current assets (used within one year):

Cash and cash equivalents
Accounts receivable (amounts owed by customers)
Inventory of goods, raw materials, and supplies
Short-term investments

Non-current assets (used for more than one year):

Fixed assets (buildings, machinery, equipment)
Intangible assets (brands, patents, software)
Long-term investments
Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets BELLUS Health

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
408 M	310 M	153 M	-	-	22.7 M	7.13 M	10.8 M	14.4 M	22.2 M	27.2 M	12.1 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
408 M	7.13 M	98.7 M

Quarterly Total Assets BELLUS Health

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	310 M	-	-	-	153 M	-	-	-	96.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
310 M	96.4 M	186 M

Total Assets of other stocks in the Biotechnology industry

Issuer	Total Assets	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	2.03 B	-	2.43 %	$ 254 M	Germany
Arbutus Biopharma Corporation ABUS	144 M	$ 4.78	-0.31 %	$ 793 M	Canada
Aclaris Therapeutics ACRS	220 M	$ 3.03	-0.49 %	$ 234 M	USA
Aeglea BioTherapeutics AGLE	608 M	-	-	$ 1.01 B	USA
Alpine Immune Sciences ALPN	287 M	-	-	$ 2.17 B	USA
AlloVir ALVR	119 M	-	4.14 %	$ 49.1 M	USA
Alexion Pharmaceuticals, Inc. ALXN	18.1 B	-	-	$ 40.3 B	USA
Aptorum Group Limited APM	16.1 M	$ 1.15	-1.71 %	$ 6.27 M	China
Ampio Pharmaceuticals AMPE	5.74 M	-	-11.43 %	$ 502 K	USA
EyeGate Pharmaceuticals, Inc. EYEG	15.2 M	-	-1.52 %	$ 24.7 M	USA
Applied Molecular Transport AMTI	107 M	-	-	$ 10.1 M	USA
Midatech Pharma plc MTP	14.8 M	-	-18.52 %	$ 27.3 M	Britain
Ascendis Pharma A/S ASND	1.18 B	$ 209.39	-1.61 %	$ 5 B	Danmark
Aptevo Therapeutics APVO	15.6 M	$ 0.6	-35.8 %	$ 166 K	USA
Alterity Therapeutics Limited ATHE	41.4 M	$ 3.12	0.81 %	$ 7.51 B	Australia
Biophytis SA BPTS	12 M	-	-13.47 %	$ 169 M	France
BioVie BIVI	21.6 M	$ 1.2	-5.51 %	$ 1.77 M	USA
Athersys ATHX	60.2 M	-	3.77 %	$ 22.4 M	USA
Институт стволовых клеток человека ISKJ	1.51 B	-	-	-	Russia
Avenue Therapeutics ATXI	2.67 M	-	-52.27 %	$ 4.45 M	USA
ARCA biopharma ABIO	396 M	-	1052.0 %	$ 415 M	USA
AVROBIO AVRO	101 M	-	1083.1 %	$ 745 M	USA
Can-Fite BioPharma Ltd. CANF	9.12 M	$ 0.22	24.46 %	$ 479 M	Israel
Acasti Pharma ACST	72 M	-	4.01 %	$ 150 M	Canada
Adaptimmune Therapeutics plc ADAP	283 M	-	-15.15 %	$ 60.3 M	Britain
BioDelivery Sciences International BDSI	325 M	-	-4.8 %	$ 255 M	USA
Albireo Pharma ALBO	302 M	-	-0.23 %	$ 916 M	USA
BioNTech SE BNTX	22.5 B	$ 94.72	-0.33 %	$ 27.2 B	Germany
Amphastar Pharmaceuticals AMPH	1.58 B	$ 27.09	1.04 %	$ 1.31 B	USA
BeiGene, Ltd. BGNE	5.92 B	-	0.49 %	$ 251 B	Cayman-islands
Anika Therapeutics ANIK	271 M	$ 9.6	1.27 %	$ 141 M	USA
Bellicum Pharmaceuticals BLCM	23.8 M	-	-9.72 %	$ 5.89 M	USA
Berkeley Lights BLI	226 M	-	-7.31 %	$ 87 M	USA
bluebird bio BLUE	619 M	-	-	$ 546 M	USA
Arena Pharmaceuticals ARNA	785 M	-	-6.81 %	$ 3.04 B	USA
Acer Therapeutics ACER	11.6 M	-	2.71 %	$ 14 M	USA
Calithera Biosciences CALA	64.8 M	-	-10.95 %	$ 876 K	USA
Axon Enterprise AXON	4.47 B	$ 584.81	-1.07 %	$ 44.3 B	USA
Cellectar Biosciences CLRB	12.1 M	$ 2.53	-8.33 %	$ 30.9 M	USA
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel
Aytu BioScience AYTU	124 M	$ 2.44	-3.56 %	$ 15.3 M	USA
AstraZeneca PLC AZN	104 B	$ 92.79	0.37 %	$ 96.9 B	Britain
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Catalyst Biosciences CBIO	117 M	$ 12.33	-0.29 %	$ 812 M	USA
Brickell Biotech BBI	11.6 M	-	-5.38 %	$ 6.06 M	USA
Burford Capital Limited BUR	3.11 B	$ 9.1	1.0 %	$ 1.48 B	Britain
Celldex Therapeutics CLDX	792 M	$ 26.29	-2.01 %	$ 1.69 M	USA
Biohaven Pharmaceutical Holding Company Ltd. BHVN	1.08 B	$ 11.07	2.45 %	$ 716 M	USA
Biogen BIIB	28 B	$ 176.45	0.07 %	$ 25.7 B	USA
Cerevel Therapeutics Holdings CERE	1.24 B	-	-	$ 7.29 B	USA